HighTower Advisors
SRPT icon

HighTower Advisors’s Sarepta Therapeutics SRPT Stock Holding History

HighTower Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-7,000
Closed -$42K – 3387
2022
Q2 		$42K Buy
+7,000
New +$515K ﹤0.01% 2921

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HighTower Advisors's SRPT Position: Q1 2026 in Review

HighTower Advisors opened a new position in Sarepta Therapeutics (SRPT) in Q1 2026: 9,769 shares worth $213K. The stake represents ﹤0.01% of the portfolio and ranks #3439 among its holdings. This is a return to the name: HighTower Advisors previously reported a position in SRPT as recently as Q3 2025.

HighTower Advisors first reported a position in SRPT in Q1 2016 and has held it in 40 quarters since. The position peaked at $7.86M in Q2 2024. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • HighTower Advisors held 9,769 shares of Sarepta Therapeutics worth $213K as of Q1 2026.
  • Sarepta Therapeutics was a new HighTower Advisors position in Q1 2026.
  • Sarepta Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3439 holding.
  • HighTower Advisors first reported a position in Sarepta Therapeutics in Q1 2016 and has held it in 40 quarters since.
  • HighTower Advisors's Sarepta Therapeutics position peaked at $7.86M in Q2 2024.
  • 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.